• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Inflamm Regen . CD147-high classical monocytes: a cellular biomarker for COVID-19 disease severity and treatment response

tetano

Editor, Senior Moderator
Inflamm Regen


. 2025 Apr 7;45(1):8.
doi: 10.1186/s41232-025-00371-8. CD147-high classical monocytes: a cellular biomarker for COVID-19 disease severity and treatment response

Teruaki Murakami[SUP] 1 2 [/SUP], Yuta Yamaguchi[SUP] 1 2 3 [/SUP], Saori Amiya[SUP] 1 2 [/SUP], Yuko Yoshimine[SUP] 1 2 [/SUP], Shinichiro Nameki[SUP] 1 2 [/SUP], Yasutaka Okita[SUP] 1 4 [/SUP], Yasuhiro Kato[SUP] 1 2 [/SUP], Haruhiko Hirata[SUP] 1 [/SUP], Yoshito Takeda[SUP] 1 [/SUP], Atsushi Kumanogoh[SUP] 1 2 5 6 7 8 [/SUP], Takayoshi Morita[SUP] 9 10 11 [/SUP]



Affiliations
Free article Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to severe coronavirus disease 2019 (COVID-19), which is characterized by cytokine storm and organ dysfunction. The spike S1 subunit induces inflammatory cytokine production, but the immune cell subsets that respond to S1 stimulation and contribute to disease severity remain unclear.
Methods: We analyzed serum samples and peripheral blood mononuclear cells (PBMCs) from patients with COVID-19 (moderate: n = 7; severe: n = 25) and healthy controls (n = 38). Using mass cytometry (cytometry by time-of-flight; CyTOF), we analyzed immune cell responses to S1 subunit stimulation in PBMCs from healthy donors and patients with COVID-19. We examined correlations among identified cell populations, serum cytokine levels, and clinical parameters.
Results: Serum S1 subunit levels correlated with disease severity and inflammatory cytokine concentrations. S1 subunit stimulation induced dose-dependent cytokine production from PBMCs, predominantly from myeloid cells. CyTOF analysis identified classical monocytes with high CD147 expression (CD147hi cMono) as the primary source of S1-induced cytokines. The proportion of CD147hi cMono increased significantly in severe COVID-19 and decreased with clinical improvement. The frequency of CD147hi cMono showed a stronger positive correlation with clinical severity markers in younger patients compared to older patients.
Conclusions: CD147hi cMono are the primary cellular source of S1-induced inflammatory cytokines and may serve as potential biomarkers for monitoring COVID-19 severity and treatment response.

Keywords: CD147; COVID-19; Classical monocyte; Cytokine storm; Inflammation; Mass cytometry; SARS-CoV-2; Spike S1 subunit.

 
Back
Top Bottom